Regulators in the U.S. and China have granted Xellsmart permission to start clinical testing of its experimental stem cell therapy in people with multiple system atrophy-Parkinsonian type (MSA-P). This is the fourth clinical trial program for Xellsmart’s stem cell therapy platform to have received regulatory clearance from both the…
